Valeant Pharmaceuticals International, Inc. VRX was a big mover last session, as the company saw its shares rise nearly 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company-as the stock is now up 28% in the past one-month time frame.
The move came after the company reported solid first-quarter 2018 results and also raised guidance for full year 2018.
The company has seen a mixed track record when it comes to estimate revisions of two increases and no decrease over the past few weeks, while the Zacks Consensus Estimate for the current quarter remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Valeant Pharmaceuticals currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.
Valeant Pharmaceuticals International, Inc. Price
Valeant Pharmaceuticals International, Inc. Price | Valeant Pharmaceuticals International, Inc. Quote
Investors interested in the Medical - Drugs industry may consider BioSpecifics Technologies Corp. BSTC , which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Is VRX going up? Or down? Predict to see what others think: Up or Down
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early. See Zacks' 3 Best Stocks to Play This Trend >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Valeant Pharmaceuticals International, Inc. (VRX): Free Stock Analysis Report BioSpecifics Technologies Corp (BSTC): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research